Product image 1

Stockley's Drug Interactions

PRODUCT CODE - PBSTOCKLEYS
£323.99 inc
£269.99 ex VAT
£269.99 ex
£323.99 inc VAT
Free Delivery when you add this item!

Reasons to buy

  • Free Delivery!
  • Easy Returns!
  • SSL Secured Transactions
×
Ask a Question about... Stockley's Drug Interactions
PRODUCT CODE - PBSTOCKLEYS

If you have a question about this product, please use the area below, click 'SUBMIT' when you're done and we'll get back to you ASAP!

Product DetailProduct Detail

Stockley?s Drug Interactions, edited by Claire L Preston, remains the world?s most comprehensive and authoritative international reference book on drug interactions. Based upon thousands of published papers and reports this eleventh edition:

  • Covers interactions between therapeutic drugs, proprietary medicines, herbal medicines, foods, drinks, and drugs of abuse
  • Contains in-depth yet concise monographs in an easy-to-read format
  • Provides comprehensive details of the clinical evidence for the interactions under discussion, an assessment of their clinical importance, and clear guidance on managing the interaction in practice
  • Has a brief summary of the interaction in each monograph ? perfect for the busy healthcare professional
  • Is fully referenced throughout
  • Contains almost 4500 monographs
  • Is global in coverage ? inclusion of drugs used worldwide


New in the 11th edition: 

  • Over 350 new monographs added
  • Many existing monographs have been reviewed, revalidated, and updated
  • A comprehensive update and restructure of the chapter on Antidiabetic drugs, in-line with published literature
  • Addition of new advice regarding the concurrent use of aliskiren, ACE inhibitors, and angiotensin-II receptor antagonists
  • An updated list of drugs that have a risk of prolonging the QT interval
  • The addition of new drugs, including apixaban, apremilast, dolutegravir, lomitapide, mirabegron, the NS5A inhibitors (daclatasvir, ledipasvir, ombitasvir), the NS5B inhibitors (dasabuvir, sofosbuvir), the sodium-glucose co-transporter-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), and telavancin